Blog
Building a vendor strategy: Protecting commercial plans from supplier-driven data risk
Explores how to build a proactive vendor strategy, pressure-test suppliers, plan for transitions, and protect commercial performance from...
Top 2026 drug launches to watch: oral breakthroughs in obesity, psoriasis, and cholesterol
Taming the complexity of CGT commercialization: 5 keys to a workable operating model
New Year, new pharma operating model: 2026 resolutions for life sciences commercialization
2026 life sciences commercialization priorities: What’s funded, in the cart, and on the wish list
From chatbots to agents: How GPT-5 is reshaping healthcare and pharma
Webinar: Rethinking Life Sciences Commercialization for 2026: What’s Working, What’s Not and What’s Next
Research premiere for ‘Commercialization that Works’; direct channels reignite pharma’s patient-centricity hopes
How AI can keep life sciences innovation moving despite funding and staffing cuts
How to confront biopharma's crisis of cohesion
The new pharma equation: How DTP, DTC, and DTE are re-wiring healthcare around patients
How to make cell and gene therapy commercialization work with Rita Johnson-Greene
Introducing Beghou Arc™: Redefining life sciences commercialization
How to make cell and gene therapy commercialization work
.png?width=400&height=250&name=Blog%20(6).png)